CASI Pharmaceuticals (CASIF) Research & Development (2022 - 2025)

CASI Pharmaceuticals has reported Research & Development for 4 years, with the latest figure at $1.2 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 91.28% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at -$3.8 million (down 143.04% YoY), and the FY2025 full-year result was $6.3 million, down 29.26% from the prior year.
• Research & Development for Q4 2025 stood at $1.2 million, up from -$1.4 million in the prior quarter.
• The five-year high for Research & Development was $14.2 million in Q4 2024, with the low at -$27.7 million in Q4 2022.
• Historically, Research & Development has averaged -$66000.0 across 4 years, with a median of $1.8 million in 2023.
• The largest YoY upside for Research & Development was 512.27% in 2024 against a maximum downside of 197.71% in 2024.
• CASI Pharmaceuticals' Research & Development stood at -$27.7 million in 2022, then surged by 108.34% to $2.3 million in 2023, then surged by 512.27% to $14.2 million in 2024, then slumped by 91.28% to $1.2 million in 2025.
• The last three Research & Development figures came in at $1.2 million (Q4 2025), -$1.4 million (Q3 2025), and -$1.7 million (Q2 2025), per Business Quant data.